Notice2025-06283
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production Activity; Merck, Sharp & Dohme LLC; (Pharmaceutical Products for Research and Development); Rahway, New Jersey
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 14, 2025
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 70 (Monday, April 14, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 70 (Monday, April 14, 2025)]
[Notices]
[Page 15541]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-06283]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-24-2025]
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production
Activity; Merck, Sharp & Dohme LLC; (Pharmaceutical Products for
Research and Development); Rahway, New Jersey
Merck, Sharp & Dohme LLC submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facility in
Rahway, New Jersey, within Subzone 49Y. The notification conforming to
the requirements of the Board's regulations (15 CFR 400.22) was
received on April 2, 2025.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product(s) and material(s)/component(s) would be added to the
production authority that the Board previously approved for the
operation, as reflected on the Board's website.
The proposed finished products include: drug products for
infectious disease; neurologic disease; oncology; immunotherapy;
cardiovascular disease; and, monoclonal antibody drug products for
neurologic disease and oncology (duty free).
The proposed foreign-status materials/components include the
following active pharmaceutical ingredients: pyridine infectious
disease; lactam cardiovascular disease, pyranol immunotherapy;
nucleoside infectious disease; furan infectious disease; pyrimidine
infectious disease; monoclonal antibody neurologic disease; pyrimidine
neurologic disease; pyridazine oncology; macrocycle infectious disease;
monoclonal antibody oncology; alkaloid oncology; macrocycle
cardiovascular disease; sulfonamide cardiovascular disease; and, pyran
neurologic disease (duty rate ranges from duty-free to 6.5%). The
request indicates that certain materials/components are subject to
duties under section 1702(a)(1)(B) of the International Emergency
Economic Powers Act (section 1702) and section 301 of the Trade Act of
1974 (section 301), depending on the country of origin. The applicable
section 1702 and section 301 decisions require subject merchandise to
be admitted to FTZs in privileged foreign status (19 CFR 146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#9dfbe9e7dde9effcf9f8b3faf2eb"><span class="__cf_email__" data-cfemail="6402101e2410160500014a030b12">[email protected]</span></a>. The closing period for their receipt is May 27, 2025.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#e1a588808f84cfa7888f978493a19593808584cf868e97"><span class="__cf_email__" data-cfemail="b7f3ded6d9d299f1ded9c1d2c5f7c3c5d6d3d299d0d8c1">[email protected]</span></a>.
Dated: April 8, 2025.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2025-06283 Filed 4-11-25; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 14, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.